JPWO2021155467A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021155467A5 JPWO2021155467A5 JP2022548039A JP2022548039A JPWO2021155467A5 JP WO2021155467 A5 JPWO2021155467 A5 JP WO2021155467A5 JP 2022548039 A JP2022548039 A JP 2022548039A JP 2022548039 A JP2022548039 A JP 2022548039A JP WO2021155467 A5 JPWO2021155467 A5 JP WO2021155467A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- hydrogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 116
- 150000001875 compounds Chemical class 0.000 claims description 102
- 229910052739 hydrogen Inorganic materials 0.000 claims description 100
- 239000001257 hydrogen Substances 0.000 claims description 100
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 72
- 150000002431 hydrogen Chemical class 0.000 claims description 69
- 125000005843 halogen group Chemical group 0.000 claims description 68
- 125000004429 atom Chemical group 0.000 claims description 54
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 51
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 51
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 49
- 229910005965 SO 2 Inorganic materials 0.000 claims description 41
- 229910020008 S(O) Inorganic materials 0.000 claims description 39
- 125000001424 substituent group Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 33
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 33
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 33
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 32
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 32
- 125000002947 alkylene group Chemical group 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 25
- 229910052805 deuterium Chemical group 0.000 claims description 25
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 22
- 125000001188 haloalkyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 125000006643 (C2-C6) haloalkenyl group Chemical group 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 12
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 10
- 125000005275 alkylenearyl group Chemical group 0.000 claims description 10
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 9
- 239000000651 prodrug Substances 0.000 claims description 9
- 125000006644 (C2-C6) haloalkynyl group Chemical group 0.000 claims description 7
- -1 C1-C20 haloalkyl Chemical group 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 5
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 4
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 101710085469 CD2 homolog Proteins 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2
- 102100036364 Cadherin-2 Human genes 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 230000003938 response to stress Effects 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 206010011906 Death Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 125000000262 haloalkenyl group Chemical group 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 208000025966 Neurological disease Diseases 0.000 description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000871 behavioral problem Toxicity 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 208000014679 binge eating disease Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000026097 Factitious disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 206010057342 Onychophagia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000023906 Sexual and Gender disease Diseases 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 208000027688 depersonalization disease Diseases 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969894P | 2020-02-04 | 2020-02-04 | |
| US62/969,894 | 2020-02-04 | ||
| PCT/CA2021/050122 WO2021155467A1 (en) | 2020-02-04 | 2021-02-04 | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512821A JP2023512821A (ja) | 2023-03-29 |
| JPWO2021155467A5 true JPWO2021155467A5 (zh) | 2024-02-13 |
Family
ID=77199114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548039A Pending JP2023512821A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11453689B2 (zh) |
| EP (1) | EP4100403A4 (zh) |
| JP (1) | JP2023512821A (zh) |
| KR (1) | KR20220137085A (zh) |
| CN (1) | CN115380028A (zh) |
| AU (1) | AU2021215709A1 (zh) |
| BR (1) | BR112022015379A2 (zh) |
| CA (1) | CA3166940A1 (zh) |
| IL (1) | IL295374A (zh) |
| MX (1) | MX2022009528A (zh) |
| WO (1) | WO2021155467A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2022229037A1 (en) * | 2021-03-02 | 2023-09-28 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| WO2023019367A1 (en) * | 2021-08-20 | 2023-02-23 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| WO2023122320A1 (en) * | 2021-12-24 | 2023-06-29 | Kuleon Llc | Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists |
| WO2023150547A2 (en) * | 2022-02-01 | 2023-08-10 | Caamtech, Inc. | Psychedelic compounds and their therapeutic uses |
| US20230202978A1 (en) | 2022-03-04 | 2023-06-29 | Reset Pharmaceuticals, Inc. | Co-crystal or salt |
| WO2023201423A1 (en) * | 2022-04-19 | 2023-10-26 | Mindset Pharma Inc. | Indoline derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559129A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| US5120749A (en) | 1991-02-20 | 1992-06-09 | Abbott Laboratories | Platelet activating antagonists |
| TW288010B (zh) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| KR0179072B1 (ko) * | 1992-04-07 | 1999-03-20 | 알렌 제이. 스피겔 | 5-ht1 작동약으로서의 인돌 유도체 |
| CN1121348A (zh) * | 1993-04-22 | 1996-04-24 | 辉瑞研究及发展公司 | 吲哚衍生物作为5-ht1类激动剂用于治疗周期性偏头痛 |
| AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| ATE258050T1 (de) | 1996-10-31 | 2004-02-15 | Harbor Branch Oceanographic | Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen |
| US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
| GB9923314D0 (en) | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
| WO2001094310A1 (en) | 2000-06-07 | 2001-12-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Methods for making bis-heterocyclic alkaloids |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| WO2004106298A1 (en) | 2003-05-30 | 2004-12-09 | Janssen Pharmaceutica N.V. | Indole derivatives with an improved antipsychotic activity |
| NZ553646A (en) | 2004-09-22 | 2010-07-30 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between MDM2 and p53 |
| BRPI0607517A2 (pt) | 2005-04-13 | 2009-09-08 | Neuraxon Inc | compostos de indol substituìdo, composição farmacêutica compreendendo o mesmo, método para tratar e uso do mesmo |
| US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| AU2007206950B2 (en) | 2006-01-19 | 2012-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
| EP2029136A4 (en) * | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | TREATMENT FOR DEPRESSION DISEASES |
| US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| WO2008036967A2 (en) | 2006-09-22 | 2008-03-27 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds as lasy activators |
| US20090014868A1 (en) | 2007-07-10 | 2009-01-15 | International Business Machines Corporation | Manufacturing ic chip in portions for later combining, and related structure |
| AU2008323526A1 (en) | 2007-11-16 | 2009-05-22 | Neuraxon, Inc. | Indole compounds and methods for treating visceral pain |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| WO2010132072A1 (en) | 2009-05-15 | 2010-11-18 | Neuraxon, Inc | Treatment or prevention of migraine by dosing at aura |
| JP5959537B2 (ja) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリジニル−ピリミジン及び医薬としてのその使用 |
| EP3160464B1 (en) * | 2014-06-26 | 2018-07-18 | Contera Pharma APS | 6-hydroxybuspirone for use in the treatment of movement disorders |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| MA42769B1 (fr) * | 2015-09-10 | 2019-12-31 | Suven Life Sciences Ltd | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
| US20200030309A1 (en) | 2016-09-29 | 2020-01-30 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| US20190358238A1 (en) | 2016-11-16 | 2019-11-28 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| EP3917537A4 (en) | 2019-01-30 | 2022-09-07 | Diamond Therapeutics Inc. | METHODS AND COMPOSITIONS USING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF MENTAL, COGNITIVE, BEHAVIORAL AND/OR MODIFICATIONS |
| BR112021017621A2 (pt) | 2019-03-07 | 2021-11-23 | Arbormentis LLC | Composições e métodos de uso compreendendo substâncias com ações de plasticidade neural administradas em dosagens e formulações não psicodélicas/psicotomiméticas |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CA3160793A1 (en) | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| EP4099995A1 (en) | 2020-02-05 | 2022-12-14 | Yale University | Psychedelic treatment for headache disorders |
| US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| IL299506A (en) | 2020-06-30 | 2023-02-01 | Reunion Neuroscience Canada Inc | Prodrugs of tryptamine |
| WO2022018709A1 (en) | 2020-07-21 | 2022-01-27 | Ai Pharmaceuticals Jamaica Limited | Compositions and methods for treatment of psychoses and psychotic disorders |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-02-04 EP EP21751045.2A patent/EP4100403A4/en active Pending
- 2021-02-04 BR BR112022015379A patent/BR112022015379A2/pt unknown
- 2021-02-04 WO PCT/CA2021/050122 patent/WO2021155467A1/en active Application Filing
- 2021-02-04 IL IL295374A patent/IL295374A/en unknown
- 2021-02-04 AU AU2021215709A patent/AU2021215709A1/en active Pending
- 2021-02-04 JP JP2022548039A patent/JP2023512821A/ja active Pending
- 2021-02-04 CA CA3166940A patent/CA3166940A1/en active Pending
- 2021-02-04 KR KR1020227030622A patent/KR20220137085A/ko unknown
- 2021-02-04 MX MX2022009528A patent/MX2022009528A/es unknown
- 2021-02-04 CN CN202180026721.8A patent/CN115380028A/zh active Pending
- 2021-07-28 US US17/387,864 patent/US11453689B2/en active Active
-
2022
- 2022-08-02 US US17/879,320 patent/US12054504B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021155470A5 (zh) | ||
| JPWO2021155468A5 (zh) | ||
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| AU2017286370B2 (en) | Heterocyclic compounds as antibacte rials | |
| JP6673939B2 (ja) | Ｇｐｒ５２に関連する障害の治療または予防に有用なｇｐｒ５２のモジュレーターとしての１−ヘテロアリール−インドリン−４−カルボキサミド | |
| JP2009538910A5 (zh) | ||
| RU93058600A (ru) | Производные пиперидина, обладающие анксиолитическим действием, фармацевтическая композиция на их основе | |
| CY1114702T1 (el) | Νεοι εναnτιομερως καθαροι βητα αγωνιστες, μεθοδος για την παραγωγη τους και χρηση αυτων ως φαρμακων | |
| JP6421185B2 (ja) | ベンゾイミダゾール−プロリン誘導体の使用 | |
| RU2006120948A (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| JP2006521345A (ja) | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 | |
| JP2017537948A (ja) | Ｎａｄｐｈオキシダーゼ阻害剤としてのアミドチアジアゾール誘導体 | |
| RU2011153723A (ru) | Обратные агонисты и антагонисты н3 рецепторов гистамина и способы их применения | |
| JPWO2021155467A5 (zh) | ||
| JP3521214B2 (ja) | ４，５−ジヒドロイソオキサゾリルアルキルピペラジン誘導体とその製造方法並びにドーパミン拮抗剤 | |
| JP6159388B2 (ja) | タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体 | |
| JP2002193954A (ja) | ドーパミンｄ３及びｄ４受容体に対して選択的活性を有する新規のイソオキサゾリルアルキルピペラジン誘導体とその製造方法 | |
| JP2023512762A (ja) | ムスカリン性受容体４アンタゴニストおよび使用方法 | |
| JP2017502069A (ja) | 有機化合物 | |
| JPH1029987A (ja) | セロトニン５−ｈｔ３受容体部分活性薬 | |
| DE69503745T2 (de) | 3-Alkoxybenzylpiperidin-Derivate as melatonergisches Mittel | |
| CA2926443A1 (en) | Heteroaryl linked quinolinyl modulators of ror.gamma.t | |
| JP2009537598A (ja) | 新規１，４−ジアザ−ビシクロ［３．２．２］ノナン誘導体及びそれらの医学的使用 | |
| WO1995007905A1 (fr) | Derive d'imidazolidinone et procede pour sa production | |
| TW421645B (en) | H3 receptor ligands of the phenyl-alkyl-imidazoles type |